...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Differences of Opinion

I expect an RTO/IPO when they can pair it with positive news -- probably Phase I results. Without that, I think we'll get the "massive liquidation event" that fouremm mentioned. They are not going to to a public listing if the stock is likely to get pounded.

Share
New Message
Please login to post a reply